Celera Presents Data Replicating Its Immunodiagnostic Assay To Detect Lung Cancer From Blood Serum
Celera Corporation (NASDAQ:CRA) announced yesterday the presentation of data replicating its novel mass spectrometry-based approach to identify and validate circulating protein biomarkers that detect non-small cell lung cancer (NSCLC) in an independent cohort of individuals with lung cancer. This study was performed in collaboration with scientists at NYU Langone Medical Center, NY. A key outcome of the study was the validation of a 9 biomarker immunoassay on a cohort of samples that is enriched for stage I disease, important for screening of early stage disease. The assay detected lung cancer with 92% sensitivity at 93% specificity. The panel also accurately distinguished malignant cases from benign lung disease. The data is being presented at the 13th World Conference on Lung Cancer as part of the International Association for the Study of Lung Cancer (IASLC) in San Francisco, CA.
Endocrinology